Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap
Philipp A. Ilinykh(Houston Methodist), Alexander Bukreyev(Galveston College), Kai Huang(Galveston College), Pavlo Gilchuk(AstraZeneca (Japan)), James E. Crowe(Vanderbilt University Medical Center), Galit Alter(Ragon Institute of MGH, MIT and Harvard), Patrick Younan(Galveston College), Rodrigo I. Santos(Universidade de São Paulo), Xiaoli Shen(Nanchang University), Bronwyn M. Gunn(Washington State University), Andrew I. Flyak(Vanderbilt University), Natalia A. Kuzmina(Galveston College)
Cited by 29
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981